相似文献
1
Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.
Chem Biol. 2010 Nov 24;17(11):1183-8. doi: 10.1016/j.chembiol.2010.10.013.
2
Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs.
Nucleic Acid Ther. 2014 Jun;24(3):199-209. doi: 10.1089/nat.2013.0476. Epub 2014 Apr 2.
3
Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway.
Nucleic Acids Res. 2012 Dec;40(22):11270-80. doi: 10.1093/nar/gks907. Epub 2012 Oct 4.
4
Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions.
Biochemistry. 2013 Dec 23;52(51):9329-38. doi: 10.1021/bi4014209. Epub 2013 Nov 27.
5
RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression.
Nucleic Acids Res. 2013 Oct;41(18):8788-801. doi: 10.1093/nar/gkt594. Epub 2013 Jul 24.
6
Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.
Ann N Y Acad Sci. 2009 Sep;1175:24-31. doi: 10.1111/j.1749-6632.2009.04975.x.
7
Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
Mol Ther. 2009 Jun;17(6):1053-63. doi: 10.1038/mt.2009.17. Epub 2009 Feb 24.
8
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.
Cell. 2012 Aug 31;150(5):895-908. doi: 10.1016/j.cell.2012.08.002.
9
Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs.
Biochemistry. 2014 Jul 22;53(28):4510-8. doi: 10.1021/bi500610r. Epub 2014 Jul 11.
10
Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
Hum Gene Ther. 2008 Jul;19(7):710-9. doi: 10.1089/hum.2007.116.
引用本文的文献
1
CAG-targeted brain-permeable therapy tested in biallelic humanized polyQ mouse models.
Mol Ther Nucleic Acids. 2025 Feb 22;36(2):102496. doi: 10.1016/j.omtn.2025.102496. eCollection 2025 Jun 10.
2
It is Time to Revisit miRNA Therapeutics.
Nucleic Acid Ther. 2025 Feb;35(1):1-5. doi: 10.1089/nat.2024.0069. Epub 2024 Nov 21.
3
Sequencing-guided design of genetically encoded small RNAs targeting CAG repeats for selective inhibition of mutant .
Mol Ther Nucleic Acids. 2024 Apr 29;35(2):102206. doi: 10.1016/j.omtn.2024.102206. eCollection 2024 Jun 11.
4
Emerging Therapies for Huntington's Disease - Focus on N-Terminal Huntingtin and Huntingtin Exon 1.
Biologics. 2022 Sep 30;16:141-160. doi: 10.2147/BTT.S270657. eCollection 2022.
5
A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease.
Mol Ther Nucleic Acids. 2022 May 5;28:702-715. doi: 10.1016/j.omtn.2022.04.031. eCollection 2022 Jun 14.
6
Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease.
Mol Ther Methods Clin Dev. 2022 Mar 4;25:84-95. doi: 10.1016/j.omtm.2022.03.001. eCollection 2022 Jun 9.
7
Difficulties translating antisense-mediated activation of Frataxin expression from cell culture to mice.
RNA Biol. 2022;19(1):364-372. doi: 10.1080/15476286.2022.2043650. Epub 2021 Dec 31.
8
Nucleic Acid-Based Therapeutic Approach for Spinal and Bulbar Muscular Atrophy and Related Neurological Disorders.
Genes (Basel). 2022 Jan 5;13(1):109. doi: 10.3390/genes13010109.
9
Reexamining assumptions about miRNA-guided gene silencing.
Nucleic Acids Res. 2022 Jan 25;50(2):617-634. doi: 10.1093/nar/gkab1256.
10
The emerging roles of long non-coding RNAs in polyglutamine diseases.
J Cell Mol Med. 2021 Sep;25(17):8095-8102. doi: 10.1111/jcmm.16808. Epub 2021 Jul 28.
本文引用的文献
1
HD Therapeutics - CHDI Fifth Annual Conference.
IDrugs. 2010 Apr;13(4):219-23.
2
Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.
Ann N Y Acad Sci. 2009 Sep;1175:24-31. doi: 10.1111/j.1749-6632.2009.04975.x.
3
Huntington's disease: silencing a brutal killer.
Exp Neurol. 2009 Dec;220(2):226-9. doi: 10.1016/j.expneurol.2009.09.017. Epub 2009 Sep 25.
4
Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine.
Bioorg Med Chem Lett. 2009 Nov 1;19(21):6181-4. doi: 10.1016/j.bmcl.2009.09.004. Epub 2009 Sep 6.
5
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.
Science. 2009 Jul 17;325(5938):336-9. doi: 10.1126/science.1173110.
6
Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs.
Nat Biotechnol. 2009 May;27(5):478-84. doi: 10.1038/nbt.1539. Epub 2009 May 3.
7
Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
Curr Biol. 2009 May 12;19(9):774-8. doi: 10.1016/j.cub.2009.03.030. Epub 2009 Apr 9.
8
Sustained effects of nonallele-specific Huntingtin silencing.
Ann Neurol. 2009 Mar;65(3):276-85. doi: 10.1002/ana.21569.
9
A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference.
Exp Neurol. 2009 Jun;217(2):312-9. doi: 10.1016/j.expneurol.2009.03.004. Epub 2009 Mar 13.
10
Getting a handle on Huntington's disease: silencing neurodegeneration.
Nat Med. 2009 Mar;15(3):252-3. doi: 10.1038/nm0309-252.
Zotero 插件